# An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

> **NCT05112965** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 49 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Bevacizumab
- **DRUG:** Pemetrexed
- **DRUG:** Paclitaxel
- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT05112965
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-01
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05112965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05112965, "An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05112965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*